Innovation and industry structure in the biomedical industry: some preliminary results

101 636 133 4 1026 document 133 wp17_2004_rasmussen.pdf application/pdf 160198 2011-09-09 10:19:49 https://vuir.vu.edu.au/101/1/wp17_2004_rasmussen.pdf 101 1 application/pdf text en public

wp17_2004_rasmussen.pdf

draft http://eprints.org/relation/hasVolatileVersion https://vuir.vu.edu.au/id/document/10930 http://eprints.org/relation/hasVersion https://vuir.vu.edu.au/id/document/10930 http://eprints.org/relation/hasIndexCodesVersion https://vuir.vu.edu.au/id/document/10930 10930 3 1735165 document 10930 indexcodes.txt text/plain 280825ede2e7294712a2b85eca5d7f5f MD5 13194 2013-02-06 18:20:53 https://vuir.vu.edu.au/101/2/indexcodes.txt 101 2 2 text/plain other Generate index codes conversion from application/pdf to indexcodes en public

indexcodes.txt

http://eprints.org/relation/isVersionOf https://vuir.vu.edu.au/id/document/133 http://eprints.org/relation/isVolatileVersionOf https://vuir.vu.edu.au/id/document/133 http://eprints.org/relation/isIndexCodesVersionOf https://vuir.vu.edu.au/id/document/133 59704 2 2392165 document 59704 lightbox.jpg image/png 80f31d61518beef9ae10082a80cf5678 MD5 54452 2020-08-13 00:45:51 https://vuir.vu.edu.au/101/4/lightbox.jpg 101 4 4 image/png other Thumbnails conversion from text to thumbnail_lightbox en staffonly

lightbox.jpg

preview.jpg

medium.jpg

small.jpg

http://eprints.org/relation/isVersionOf https://vuir.vu.edu.au/id/dark_document/59678 http://eprints.org/relation/isVolatileVersionOf https://vuir.vu.edu.au/id/dark_document/59678 http://eprints.org/relation/issmallThumbnailVersionOf https://vuir.vu.edu.au/id/dark_document/59678 archive 34 disk0/00/00/01/01 2005-10-21 2021-08-27 07:38:36 2008-08-19 18:53:45 monograph show Rasmussen Bruce 0000-0001-5779-0339 Innovation and industry structure in the biomedical industry: some preliminary results pub 320000 FOR_2008_111500 cses industry structure; biomedical industries; preliminary results; pharmaceutical industry; biotechnology Innovation in the pharmaceutical industry raises structural questions for the participants about their future roles. New technologies, and especially biotechnology, have made the industry structure more complex. Broadly speaking these technologies have been directed at two problems. One is increasing the range of drugs available to treat disease and the other is improving the efficiency of the drug discovery process - so called platform technologies. Some technologies have assisted in both areas. These new technologies have been largely developed by specialist start up companies rather than emerging from within the large pharmaceutical companies. Access to the new technologies by large pharmaceutical companies has been through alliances, service contracts and occasionally outright purchase. A handful of the new biotechnology companies has been successful in transforming themselves into large integrated companies, not dissimilar to the large pharmaceutical companies. Other companies have attempted to survive by developing different business models - contracting their research expertise to large pharma, forming alliances amongst themselves to acquire complementary technologies and offering their platform technologies on a fee for service basis. These new business models are yet to prove their viability. 2004-02 published Victoria University No. 17 59678 2 2392127 dark_document 59678 Rasmussen Bruce.pdf application/pdf c744ba1adbaf7053dda5f38299888596 MD5 107419 2020-08-13 00:35:24 101 3 3 application/pdf text Submission & Permission Form en staffonly

Rasmussen Bruce.pdf

other public working_paper Melbourne, Australia 22 Victoria University Centre for Strategic Economic Studies Includes bibliographical references: pp.20-21 FALSE